Catheter Precision, Inc.(VTAK)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $7.2M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
VTAK Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Catheter Precision, Inc. (VTAK), a Healthcare sector company. VTAK is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $7.2m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Catheter Precision, Inc. reports quarterly revenue of $1.0M, net income of $-3.3M, free cash flow of $-2.9M. Top institutional holders of VTAK by reported 13-F value include Virtu Financial, UBS Group AG, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. VTAK trades on the NYSE exchange and files with the SEC under CIK 1716621. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTAK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Catheter Precision, Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$1.0M
Net Income
Q2 2026
$-3.3M
Free Cash Flow
Q2 2026
$-2.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+95.0% YoYNet Income
-3.2% YoYOperating Income
-88.1% YoYEPS (Diluted)
Total Assets
-42.9% YoYTotal Debt
Op. Cash Flow
+10.5% YoYFree Cash Flow
+11.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $819.0K +95.0% | $420.0K -5.0% | $442.0K +3057.1% | $14.0K -36.4% | $22.0K -99.5% | $4.4M |
| Net Income | $-17.2M -3.2% | $-16.6M +76.4% | $-70.6M -162.7% | $-26.9M -7.2% | $-25.1M +30.4% | $-36.0M |
| Operating Income | $-21.1M -88.1% | $-11.2M +85.6% | $-78.1M -189.7% | $-27.0M +7.9% | $-29.3M +17.3% | $-35.4M |
| EPS (Diluted) | — | — | — | $-25.98 +89.5% | $-248.22 | — |
| Total Assets | $15.9M -42.9% | $27.8M -9.6% | $30.7M +82.6% | $16.8M -20.0% | $21.0M -37.1% | $33.4M |
| Total Debt | $3.1M | — | — | — | — | — |
| Operating Cash Flow | $-8.3M +10.5% | $-9.3M +55.0% | $-20.6M +8.6% | $-22.6M +18.3% | $-27.6M +2.4% | $-28.3M |
| Free Cash Flow | $-8.3M +11.0% | $-9.3M +54.9% | $-20.7M +8.4% | $-22.6M +19.0% | $-27.9M +1.7% | $-28.4M |
Get alerted when VTAK's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Catheter Precision, Inc. including:
Top Institutional Holders of VTAK
Virtu Financial LLC
$17.0K19,861 shUBS Group AG
$14.5K17,061 shGEODE CAPITAL MANAGEMENT, LLC
$10.2K11,977 shTower Research Capital LLC (TRC)
$8.0K9,452 shOSAIC HOLDINGS, INC.
$7.3K8,540 shAllworth Financial LP
$255.00300 shCITIGROUP INC
$19.0022 shPurpose Unlimited Inc.
$9.0013 shHARBOUR INVESTMENTS, INC.
$7.008 shSBI Securities Co., Ltd.
$4.005 sh
| Fund | Value | Shares |
|---|---|---|
| Virtu Financial LLC | $17.0K | 19,861 |
| UBS Group AG | $14.5K | 17,061 |
| GEODE CAPITAL MANAGEMENT, LLC | $10.2K | 11,977 |
| Tower Research Capital LLC (TRC) | $8.0K | 9,452 |
| OSAIC HOLDINGS, INC. | $7.3K | 8,540 |
| Allworth Financial LP | $255.00 | 300 |
| CITIGROUP INC | $19.00 | 22 |
| Purpose Unlimited Inc. | $9.00 | 13 |
| HARBOUR INVESTMENTS, INC. | $7.00 | 8 |
| SBI Securities Co., Ltd. | $4.00 | 5 |
More Healthcare Companies
View all Healthcare →Put VTAK on your watchlist
Track score changes the day Catheter Precision, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VTAK a good stock to buy?
13F Pro's AI-powered analysis of Catheter Precision, Inc. (VTAK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VTAK are available on the VTAK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VTAK is classified as a small company.
Which hedge funds own VTAK?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VTAK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Catheter Precision, Inc.'s investment landscape.